IsoPlexis’ Single-Cell Secretome Identifies Highly Polyfunctional Superhero Cells Predicting Clinical Outcomes

Technology Webinar Discusses How IsoPlexis’ Functional Proteomics Fills the Translational Gaps in Single Cell Research

In a recent webinar, IsoPlexis discussed the impact of the unique IsoLight platform on the pioneering field of single cell research, across several disciplines. The IsoPlexis platform has the unique ability to identify polyfunctional subsets of cells which affect outcomes such as persistence and durability of response, patient stratification, tumor resistance, toxicity, and immune suppression. Unlike bulk averaging alone, the addition of single-cell proteomics allows for more precise analysis of these highly functional superhero or cells, which are predictive of patients’ clinical outcomes.

Using the IsoLight, both single cell and ultra-small sample volume proteomic analyses are fully automated, with data sent directly to the IsoSpeak software and presented through intuitive visualizations. The uniquely proteomic barcoded single cell chips that run on the IsoLight system enable highly sensitive reactions to detect cytokines released directly from single cells. With the IsoLight, a process that would traditionally require multiple instruments and steps is accomplished and one system and a variety of chip options to suit your research needs– everything from incubation to antibody binding and wash cycle is fully automated. Our automated proteomics workflow accelerates the research process and increases your work-away time, pushing forward discoveries in the fields of cancer immunology, cell and gene therapy, infectious diseases and vaccines, inflammation and neurology, and cancer signaling pathways.

Explore Research Tackling Cancer, Vaccines, Inflammation & More with IsoPlexis’ Platform

Recently, the IsoPlexis platform has been featured in several high-impact publications across disciplines including immunology, cancer immunology, and vaccine development.

  • A study by Parisi et al. published in Nature Communications used the IsoPlexis platform to show mechanistic upregulation of patients’ NK cells after a novel agonist therapy, corresponding with persistence in solid tumors. Single-cell Secretome technology was used to profile translational insights between early stage development of combination PEG-IL2 with ACT therapy. In response to PEG-IL2, researchers saw upregulated polyfunctionality in mouse immune cells, which correlated with increases of proliferation, homing, and anti-tumor T cell persistence in vivo. In patients with melanoma, researchers observed superior anti-tumor activity as well as an increase in polyfunctional T and NK cells in peripheral blood.1
  • A study by Li et al., published in Gastroenterology, used the Single-Cell Secretome technology to identify highly polyfunctional subsets of CAR-T cells in solid tumor liver cancer, and found a direct correlation between pre-clinical outcome and presence of highly polyfunctional cells. Single-cell functional phenotyping revealed that GPC3-targeted hYP7 CAR-T cells inhibited Wnt signaling and promoted apoptosis in tumor cells. The researchers also found that polyfunctional hYP7 CAR-T cells showed antigen-persistence and expansion leading to tumor regression in HCC mouse models, making hYP7 CAR-T products a potential candidate for the treatment of liver cancer.2
  • In a study by Zhou et al., published in Human Vaccines & Immunotherapeutics, IsoPlexis’ Single-Cell Secretome solution analyzed the PfSPZ anti-malaria vaccine and identified a subset of polyfunctional hepatic CD8+ T cells in vaccinated mice that were exposed to malaria. The researchers analyzed the cytokines and chemokines secreted by these polyfunctional cell subsets, and identified several which were associated with protective T cell responses to diseases such as malaria.3

To learn more about IsoPlexis’ predictive functional proteomics, watch the webinar, “Unique Functional Biology Revealed with IsoPlexis’ Functional Proteomics and Single-Cell Secretome Solution” now.

References:

  1. Parisi G, et al. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications 11: 660, 2020
  2. Li D, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology 158: 2250-2265, 2020.
  3. Zhou J, et al. CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay. Human Vaccines & Immunotherapeutics 13: 1625-1629, 2017.YP7 CAR-T products for the treatment of patients with liver cancer.
Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.